News

Though minocycline therapy has been effective in treating acne, it can often leave erythema and hyperpigmentation which can be mitigated via Intense Pulsed Light.

On the heels of the FDA approval of viloxazine extended-release capsules for adult ADHD, a neuropsychiatrist discusses the state of care and diagnosis among older patients.

In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini provide insight from ATTD 2022, including the latest updates in the world of diabetes smartphone apps, smart insulin pens, and CGM systems.

The pandemic has removed some of the barriers of medicine.

Phone communication may have decreased in recent years among doctors.

In the first episode of this new game show, a team of ARVO 2022 investigators work to invent an innovative clinical trial.

Many people struggled with anxiety during the COVID-19 pandemic.

Data show 7 risk factors, many potentially modifiable, accounted for 85% of the risk of first AMI in young women and men.

Exact triggers in acute urticaria and chronic urticaria are largely unknown, with the success of identifying causes of AU varying between 21-68%.

From curative stem cell approaches to in-clinic subretinal injections, Arshad Khanani, MD, MA, navigates what the future drug class may entail.

There remains a need for more doctors that specialize in geriatrics.

An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.

Many patients, particularly older ones, are taking unnecessary medications.

The current registered dosing of the therapy is 30 mg twice daily, but the analyzed dosage of 20 mg has not yet been approved.

Early-stage prevention of modifiable risk factors may contribute to the prevention of neurodegenerative changes and diabetic retinopathy.

Similarly, patients affected by alopecia areata had higher odds of developing psoriasis.

Study author Arshad Khanani, MD, MA, discusses how the novel-targeting gene therapy candidate may uniquely benefit patients with treated retina disease.

The participants included more than 2,000 pregnant individuals at higher risk of preeclampsia.

AstraZeneca announced the phase 3 DELIVER trial has met its primary endpoint, with use of dapagliflozin associated with a statistically significant and clinically meaningful reduction in the primary composite endpoint of CV death or worsening heart failure in patients with HFmrEF and HFpEF.

Dr. Christine Rauscher details immunotherapy for seasonal allergies, which affect roughly 20 millions adults in the US

Theodore Leng, MD, MS, discusses his team's IRIS registry findings suggesting a need for quantifying how vision-loss patients are impacted by functional or quality-of-life measures.

The Lumipulse G β-Amyloid Ratio is the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimers disease.

Study investigators used data from midlife checkpoints and late life checkpoints for participants without heart failure.

Data show half of all eyes with CRVO were still being treated at 36-months.

New 5-year data shows psoriasis improvement was similar among patients with and without metabolic syndrome, regardless of which dose they received.

Treatment delay and steroid usage were both associated with worse improvements in long term BVA and CST in patients with RVO-related macular edema.

Previous data suggests that lower antioxidant status in early life is associated with allergic status in childhood, which implies that antioxidant use could be beneficial in the management of atopic dermatitis.

Data from a pivotal trial presented at ATTD 2022 demonstrate the use of the iLet Bionic Pancreas was associated with significant improvements in HbA1c and TIR among a diverse study population of adults and children with type 1 diabetes compared with standard care.